GenSight Biologics Reports Cash Position and Revenue from Early Access Program as of March 31, 2026

GenSight Biologics Confirms Definitive Full-Year 2025 Consolidated Financial Results Are in Line with Estimates

GenSight Biologics Reports Estimated Full-Year Consolidated Financial Results for 2025

The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ®

GenSight Biologics Announces the Closing of its Nearly €1.7 Million Fundraising

GenSight Biologics Announces Successful Fundraising Worth Nearly €1.7 Million

GenSight Biologics Provides Updates about GS010/LUMEVOQ® Early Access Programs and the Ongoing REVISE Study

GenSight Biologics Bolsters Regulatory Leadership in US and Europe with Two Senior Appointments

The 15-20 National Hospital and GenSight Biologics announce the treatment of the first patient in the GS010/LUMEVOQ® REVISE Study

GenSight Biologics Announces the Results of its Extraordinary General Meeting of January 28, 2026